A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

NCT06337617 · clinicaltrials.gov ↗
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Novartis Pharmaceuticals